Lytix Biopharma ASA (OSL:LYTIX)

Norway flag Norway · Delayed Price · Currency is NOK
10.40
+0.50 (5.05%)
Apr 24, 2026, 4:25 PM CET
Market Cap761.31M +124.4%
Revenue (ttm)n/a
Net Income-59.98M
EPS-0.88
Shares Out76.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,064
Average Volume58,712
Open10.25
Previous Close9.90
Day's Range9.72 - 10.40
52-Week Range5.00 - 11.90
Beta-0.49
RSI54.33
Earnings DateMay 21, 2026

About Lytix Biopharma ASA

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as he... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 14
Stock Exchange Oslo Børs
Ticker Symbol LYTIX
Full Company Profile

Financial Performance

Financial Statements